Please login to the form below
patritumab
This page shows the latest patritumab news and features for those working in and with pharma, biotech and healthcare.
Daiichi gets breakthrough status for pre-NDA leukaemia drug
of HER3 inhibitor patritumab in combination with Roche’s EGFR drug Tarceva (erlotinib) in the same indication on disappointing efficacy data. ... Patritumab is still in mid-stage testing for head and neck cancer.
Latest news
-
Daiichi pulls study of patritumab in lung cancer
Daiichi Sankyo has halted a late-stage trial of its HER3 inhibitor patritumab after seeing no evidence of efficacy at an interim analysis. ... This particular result does not directly affect the science of patritumab in other settings," said Yver.
-
Daiichi Sankyo to shut down German antibody unit U3
cancer. . U3 Pharma's lead candidate patritumab (U3-1287), an anti-HER3 antibody in clinical trials for non-small cell lung cancer (NSCLC), breast cancer and head and neck cancer, was
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
- NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!
-
EXCELLENT DAY RATES AVAILABLE
-
Midweight Brand Planner
-
Up to £50, 000
- Head of Partnerships - Competitive - London
-
Competitive Salary Offered
Subscribe to our email news alerts
- Grail’s multi-cancer blood test gets FDA breakthrough status
- Moving annual total (MAT)
- Communique - Communiqué Awards
- Babylon expansion sparks ‘NHS destruction’ warnings
- Spinraza managed access deal in England breaks deadlock for Biogen
- Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
- There is no such thing as good medical communications
- Genentech forges $800m autoimmune alliance with Parvus
- So far so good for Amgen's much-anticipated KRAS inhibitor
- It’s OK to not be OK: Bedrock breaks down mental health stigma
- After discount row, NICE finally says yes to first line Revlimid
- Transitions in healthcare
PMHub
Hayward Medical Communications
Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...
Latest intelligence
- Investing in our People
- As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....
- Body image and mental health: The psoriasis connection
- As part of mental health awareness week, the Mental Health Foundation (MHF) have released a new report on the interaction between body image and mental health. Our Medical Writer Alex...
- It’s not the end of the world, is it?
- Industry change isn’t always gradual – it can be apocalyptic...
Quick links
Infographics
